Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry

IMPORTANCE: Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported. OBJECTIVE:...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Cardiol
Главные авторы: Hira, Ravi S., Vemulapalli, Sreekanth, Li, Zhuokai, McCabe, James M., Rumsfeld, John S., Kapadia, Samir R., Alam, Mahboob, Jneid, Hani, Don, Creighton, Reisman, Mark, Virani, Salim S., Kleiman, Neal S.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2017
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710589/
https://ncbi.nlm.nih.gov/pubmed/28636718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.1685
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы